NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

TB & Outbreaks Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB & Outbreaks Week

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Flu Vaccines



Studies from R.A. Karron and co-researchers in the area of flu vaccines published



March 31st, 2009

According to recent research published in the Journal of Infectious Diseases, "Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 10(7)-TCID50 doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intra-nasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses."

"The vaccine was well tolerated; vaccine shedding was minimal. After 2 doses, 92% of H9-seronegative participants had >= 4-fold increases in hemagglutination-inhibition antibody, and 79% had >= 4-fold increases in neutralizing antibody; 100%...


Source: TB & Outbreaks Week (2009-03-31)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login